Reason for referral to paediatric HIV virtual clinic, episodes by year (N=234)
| Referral reason | N=234 | 2009* (%) N=16 | 2010 (%) N=45 | 2011 (%) N=56 | 2012 (%) N=57 | 2013 (%) N=60 |
|---|---|---|---|---|---|---|
| Control of viraemia | ||||||
| Virological failure | 103 | 11 | 24 | 20 | 23 | 26 |
| Restart HAART | 16 | 2 | 4 | 2 | 7 | 1 |
| Start first line HAART | 8 | 0 | 2 | 1 | 1 | 4 |
| Simplification of regimen | 57 | 3 | 10 | 19 | 14 | 11 |
| Drug toxicity | ||||||
| Dyslipidaemia | 27 | 2 | 3 | 10 | 7 | 5 |
| Abnormal liver function | 11 | 0 | 1 | 3 | 3 | 4 |
| Renal toxicity | 9 | 1 | 1 | 1 | 3 | 3 |
| Hypersensitivity | 2 | 0 | 0 | 1 | 1 | 0 |
| Neurological side effects | 2 | 0 | 1 | 0 | 1 | 0 |
| Other complications | 5 | 0 | 2 | 1 | 1 | 1 |
| Other | ||||||
| Change to newer therapy | 7 | 0 | 0 | 1 | 1 | 5 |
| Thrombocytopenia | 4 | 1 | 1 | 1 | 0 | 1 |
| Poor immune reconstitution | 3 | 1 | 1 | 0 | 0 | 1 |
| Infant PEP | 2 | 0 | 0 | 1 | 0 | 1 |
| Coinfection HIV/TB | 1 | 0 | 0 | 0 | 0 | 1 |
| Other | 1 | 0 | 0 | 0 | 0 | 1 |
| Total | 234 | 16 | 45 | 56 | 57 | 60 |
*Three-month data.
HAART, highly active antiretroviral therapy; PEP, postexposure prophylaxis for infant born to HIV-infected mother.